Participants in the study will be randomly assigned to receive either apixaban or warfarin. The study will last for about three months, during which time the participants will take their assigned medication. The progress of the blood clot resolution will be monitored using a test called a transthoracic echocardiogram (TTE), which is a type of ultrasound that looks at the heart. If the TTE does not provide clear results, other imaging tests like magnetic resonance imaging (MRI) or computed tomography (CT) may be used.

Throughout the study, researchers will also keep track of any bleeding events, as both medications can increase the risk of bleeding. They will look at different types of bleeding, such as bleeding in the brain or gastrointestinal bleeding, and will also monitor for any major heart-related events. The study aims to provide valuable information on the best treatment option for patients with blood clots in the heart following a heart attack.

The purpose of the study is to evaluate the impact of these medications on the overall health of patients with intra-cardiac thrombus over a period of six months. Participants in the study will be randomly assigned to receive one of the medications or a placebo. The study will monitor the effects of the medications on the reduction of blood clots and any potential side effects, such as bleeding. The goal is to determine which medication provides the best balance of benefits and risks for patients.

Throughout the study, participants will undergo regular check-ups and imaging tests, such as echocardiography or cardiac MRI, to assess the presence and size of the blood clots. The study will last for up to six months, during which time the participants’ health and response to the treatment will be closely monitored. The findings from this study aim to improve the treatment options available for patients with intra-cardiac thrombus, ultimately enhancing their quality of life and health outcomes.

The purpose of the study is to estimate how many patients experience the resolution of the blood clot in the heart and whether they have any new brain infarctions, which are areas of dead tissue due to lack of blood supply, after three months of treatment. The study will compare the effects of dabigatran etexilate and phenprocoumon over a period of three months. Some participants will receive a placebo, which is a substance with no active medication, to help compare the effects of the actual medications.

Participants in the study will take the medication or placebo for up to three months. During this time, they will be monitored for any changes in their condition, including the resolution of the blood clot and any new brain infarctions. The study will also track any bleeding events that occur during the treatment period and for up to one year afterward. This information will help researchers understand the effectiveness and safety of these treatments for patients with left ventricular thrombosis after a STEMI.